Peyton Howell

Peyton Howell is Chief Operating and Growth Officer responsible for Parexel’s operational delivery,  strategy and growth. Peyton’s focus is on driving collaboration and innovation across the company’s 18,000+ colleagues to deliver more integrated solutions that meet patient needs and drive customer success.

Peyton joined Parexel in 2018 and most recently was President, Consulting and Chief Commercial & Strategy Officer leading the company to record new business growth and creation of a patient-focused strategy.  

Peyton has more than 25 years of leadership experience in the healthcare industry and prior to joining Parexel held several leadership positions with AmerisourceBergen, a Fortune 20 company, most recently as President for Health Systems and Specialty Care Solutions, a $50B business unit. She also was President, Global Sourcing and Manufacturer Relations, responsible for leadership of $150B in manufacturer sourcing relationships. In this role, she led the creation of a new sourcing entity in Bern, Switzerland to support global manufacturer relations and a joint venture with Walgreens. Peyton previously served as President, Consulting Services for the company, managing a portfolio of industry-leading pharma services (including acquisitions) focused on market access, reimbursement, patient programs, specialty pharmacy, specialty logistics and product commercialization.

Peyton was a founder of Lash Group, growing the company from an early innovator of patient access services to nearly 5,000 employees and serving as President for nearly 10 years following its acquisition by AmerisourceBergen.

Peyton holds a Masters’ in Healthcare Administration (MHA) from The Ohio State University and a Bachelor of Arts in Speech Communication from The University of Illinois at Urbana-Champaign. In 2020 she was named a Luminary by the Healthcare Businesswomen’s Association (HBA). Peyton serves on the Board of Directors of Tandem Diabetes Care (NASDQ: TNDM), a medical device manufacturer, and represents Parexel on the Board of Directors for the Association of Clinical Research Organizations (ACRO).